Harmony Biosciences Holdings, (id:6434 HRMY)
34.07 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:57:30 PM)
Exchange closed, opens in 1 day 17 hours
About Harmony Biosciences Holdings,
Market Capitalization 1.89B
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
| Headquarters (address) |
630 West Germantown Pike Plymouth Meeting 19462 PA United States |
| Phone | 484 539 9800 |
| Website | https://www.harmonybiosciences.com |
| Employees | 246 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | HRMY |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 28.14 - 41.61 |
| Market Capitalization | 1.89B |
| P/E trailing | 15.67 |
| P/E forward | 10.14 |
| Price/Sale | 2.77 |
| Price/Book | 3.16 |
| Beta | 0.770 |
| EPS | 2.11 |
| EPS United States (ID:6, base:3402) | 24.25 |